Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

Sep 23 2016

• By Derrick Gingery

Related Content

Lessons From <em>Avastin</em>: Accelerated Approval Needs “Easy On, Easy Off” Mechanism, Pazdur Says

Nov 26 2012

FDA Refuses To File Translarna NDA; PTC Plummets

Feb 24 2016

DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?

Sep 25 2016

Santhera Setback Could Have Wide-Reaching Effects For DMD Drugs

Jul 14 2016

Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations

Sep 20 2016

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

Jan 15 2016

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Related Companies

Sarepta Therapeutics, Inc.

PTC Therapeutics, Inc.

Santhera Pharmaceuticals

Genentech, Inc.

Additional Topics

United States Approvals Clinical Trials Regulation Commercial BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window